It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 13% over the past three months. However, stock prices are usually driven by a company ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Innovative technology represents a breakthrough scientific achievement for one of the most common feline infectious diseases RAHWAY, N.J., September 24, 2024--(BUSINESS WIRE)--Merck Animal Health ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

The agreement grants Merck the option to license Evaxion’s preclinical vaccine candidates EVX-B2 and EVX-B3. Evaxion also granted Merck an option to license preclinical vaccine candidates EVX-B2 ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech that spans ...